Skip to main content
. 2022 Sep 8;7(17):e161820. doi: 10.1172/jci.insight.161820

Figure 4. DT2216 induces degradation in vivo in FLC PDX.

Figure 4

PDX mice were treated with a single dose of the i.p. formulation, and tumor tissue was collected from the tumor and liver of each mouse. Each time point represents an independent mouse. BCL-XL level was monitored using Western blotting. GAPDH was used as a loading control for all immunoblot analysis presented. Data were corrected with a normalization factor against GAPDH and are presented as a percentage of the vehicle-treated (Base) cells as a control. The upper panel shows the immunoblots, and the lower panel shows the densiometric analysis performed using LI-COR. (A) PDX 34 treated with the i.p. formulation in tumor and liver samples, along with the vehicle control. (B) PDX 31 treated with the i.p. formulation in tumor and liver samples. (C) PDX 32 treated with the i.p. formulation in tumor and liver samples.